Federal reviewer recommends pharmaceutical sales of Cornerstone's low salt drug; Against Approval Of Lixivaptan To Treat Hyponatremia

Federal reviewer recommends pharmaceutical sales of Cornerstone's low salt drug
MedReps
Pharmaceutical sales recruiters are keeping a close eye on Cornerstone Therapeutics after a clinical reviewer recommended that the Food and Drug Administration (FDA) approve the company's new low salt drug, lixivaptan.

Cornerstone (CRTX) Tumbles After FDA Committee Votes Against Hyponatremia ... iStockAnalyst
Cornerstone:FDA Panel Votes Against Approval Of Lixivaptan To Treat Hyponatremia

To see the animated menu and order online

Restaurant foods for takeout, catering, business meetings, team lunches, conferences, and sporting events.